X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (140) 140
index medicus (96) 96
pharmacokinetics (81) 81
female (71) 71
oncology (71) 71
pharmacology & pharmacy (68) 68
middle aged (59) 59
chemistry, analytical (58) 58
male (58) 58
aged (53) 53
adult (46) 46
cancer (43) 43
mass spectrometry (43) 43
metabolites (38) 38
animals (37) 37
biochemical research methods (37) 37
antineoplastic agents - pharmacokinetics (36) 36
reproducibility of results (36) 36
neoplasms - drug therapy (35) 35
liquid chromatography (29) 29
administration, oral (28) 28
mice (28) 28
chromatography, high pressure liquid - methods (26) 26
analysis (25) 25
sensitivity and specificity (25) 25
tandem mass spectrometry - methods (25) 25
antimitotic agents (24) 24
antineoplastic agents (24) 24
metabolism (23) 23
paclitaxel (23) 23
area under curve (21) 21
plasma (21) 21
infusions, intravenous (20) 20
paclitaxel - administration & dosage (20) 20
paclitaxel - pharmacokinetics (20) 20
pharmacology (20) 20
spectrometry, mass, electrospray ionization - methods (20) 20
neoplasms - metabolism (19) 19
spectroscopy (19) 19
lc-ms/ms (18) 18
phase-i (18) 18
validation (18) 18
antineoplastic agents - blood (17) 17
chromatography, high pressure liquid (17) 17
p-glycoprotein (17) 17
performance liquid-chromatography (17) 17
care and treatment (16) 16
chromatography, liquid - methods (16) 16
research (16) 16
tandem mass-spectrometry (16) 16
therapy (16) 16
antineoplastic agents - administration & dosage (15) 15
antineoplastic agents, phytogenic - pharmacokinetics (15) 15
biological availability (15) 15
chemotherapy (15) 15
docetaxel (15) 15
dose-response relationship, drug (15) 15
calibration (14) 14
pharmacology/toxicology (14) 14
bioanalysis (13) 13
drug administration schedule (13) 13
medicine & public health (13) 13
mice, knockout (13) 13
therapeutic drug monitoring (13) 13
biochemistry & molecular biology (12) 12
human plasma (12) 12
reference standards (12) 12
5-fluorouracil (11) 11
cancer research (11) 11
capecitabine (11) 11
excretion (11) 11
linear models (11) 11
nucleotides (11) 11
ritonavir (11) 11
taxoids - pharmacokinetics (11) 11
topotecan (11) 11
antineoplastic agents - therapeutic use (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
breast neoplasms - drug therapy (10) 10
deoxycytidine - analogs & derivatives (10) 10
dihydropyrimidine dehydrogenase (10) 10
drug (10) 10
drug stability (10) 10
methods (10) 10
taxol (10) 10
treatment outcome (10) 10
tumors (10) 10
usage (10) 10
aged, 80 and over (9) 9
antineoplastic agents - adverse effects (9) 9
antineoplastic agents, phytogenic - administration & dosage (9) 9
bioavailability (9) 9
cells (9) 9
chromatography (9) 9
cisplatin (9) 9
cremophor el (9) 9
dogs (9) 9
in-vitro (9) 9
lc–ms/ms (9) 9
maximum tolerated dose (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Cancer, ISSN 0020-7136, 01/2012, Volume 130, Issue 1, pp. 223 - 233
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2013, Volume 35, Issue 12, pp. 1946 - 1954
Journal Article
International Journal of Cancer, ISSN 0020-7136, 05/2013, Volume 132, Issue 10, pp. 2439 - 2447
Paclitaxel is avidly transported by P‐glycoprotein (P‐gp/MDR1/ABCB1). This results in low oral bioavailability, which can be boosted by coadministration of... 
P‐glycoprotein (P‐gp/MDR1) | paclitaxel | CYP3A4 | oral bioavailability | ritonavir | P-glycoprotein (P-gp/MDR1) | PLUS CYCLOSPORINE | GUT WALL | PHASE-II | KNOCKOUT MICE | CANCER | MDR1 | INHIBITION | METABOLISM | ONCOLOGY | SYSTEMIC EXPOSURE | ABSORPTION | P-glycoprotein (P-gp | Cytochrome P-450 Enzyme Inhibitors | Area Under Curve | Humans | Cytochrome P-450 Enzyme System - metabolism | Biological Availability | Male | Paclitaxel - pharmacokinetics | Intestinal Absorption | Enzyme Inhibitors - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Ritonavir - therapeutic use | Ritonavir - pharmacology | Paclitaxel - blood | Paclitaxel - administration & dosage | Antineoplastic Agents, Phytogenic - pharmacokinetics | Taxoids - blood | Antineoplastic Agents, Phytogenic - blood | Ritonavir - administration & dosage | Administration, Oral | Docetaxel | Enzyme Inhibitors - pharmacology | ATP Binding Cassette Transporter, Subfamily B, Member 1 - deficiency | Enzyme Inhibitors - therapeutic use | ATP Binding Cassette Transporter, Subfamily B | ATP Binding Cassette Transporter, Subfamily B, Member 1 - genetics | Mice, Knockout | Taxoids - pharmacokinetics | ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Taxoids - administration & dosage | Cytochrome P-450 Enzyme System - deficiency | Animals | Cytochrome P-450 CYP3A - metabolism | Cytochrome P-450 Enzyme System - genetics | Mice | Infusions, Intravenous | Chemotherapy | Glycoproteins | Bioavailability | Rodents
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2016, Volume 34, Issue 3, pp. 227 - 234
Journal Article
Analytical and Bioanalytical Chemistry, ISSN 1618-2642, 8/2019, Volume 411, Issue 20, pp. 5331 - 5345
A novel method was developed and validated for the quantification of the three approved CDK4/6 inhibitors (abemaciclib, palbociclib, and ribociclib) in both... 
Biochemistry, general | Plasma | Food Science | Palbociclib | Ribociclib | Laboratory Medicine | Tissue homogenates | Abemaciclib | LC-MS/MS | Chemistry | Analytical Chemistry | Monitoring/Environmental Analysis | Characterization and Evaluation of Materials | CHEMISTRY, ANALYTICAL | LC-MS | TISSUE | BIOCHEMICAL RESEARCH METHODS | QUANTITATIVE-ANALYSIS | PD 0332991 | CANCER | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Purines - pharmacology | Humans | Pyridines - analysis | Benzimidazoles - analysis | Piperazines - pharmacology | Animals | Piperazines - analysis | Protein Kinase Inhibitors - analysis | Aminopyridines - pharmacology | Benzimidazoles - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Purines - analysis | Pyridines - pharmacology | Chromatography, Liquid - methods | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Tandem Mass Spectrometry - methods | Aminopyridines - analysis | Ethylenediaminetetraacetic acid | Liquid chromatography | Spectrum analysis | Analysis | Liver | Methods | Brain | Matrices (mathematics) | Correlation coefficients | Tissues | Small intestine | Cyclin-dependent kinase 4 | Blood plasma | Pretreatment | Spleen | Correlation coefficient | Spectroscopy | Elution | Kidneys | Ions | Mass spectroscopy | Stability analysis | Calibration | Chromatography | Dilution | Inhibitors | Human performance | Storage conditions | Acetonitrile | Scientific imaging | Mass spectrometry | Research Paper
Journal Article
Journal Article
Clinical pharmacokinetics, 04/2019, Volume 58, Issue 10, pp. 1221 - 1236
Phase 0 microdose trials are exploratory studies to early assess human pharmacokinetics of new chemical entities, while limiting drug exposure and risks for... 
Index Medicus
Journal Article
British Journal of Cancer, ISSN 0007-0920, 04/2017, Volume 116, Issue 11, pp. 1415–1424 - 1424
BACKGROUND: We investigated the predictive value of dihydropyrimidine dehydrogenase (DPD) phenotype, measured as pretreatment serum uracil and dihydrouracil... 
5-fluorouracil | toxicity | capecitabine | uracil | dihydropyrimidine dehydrogenase | fluoropyrimidines | Fluoropyrimidines | Dihydropyrimidine dehydrogenase | Capecitabine | Toxicity | Uracil | RATIOS | DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY | CHEMOTHERAPY | PLASMA | COLORECTAL-CANCER PATIENTS | PHARMACOKINETICS | ONCOLOGY | DIHYDROURACIL | DPD DEFICIENCY | DPYD VARIANTS | Predictive Value of Tests | Capecitabine - metabolism | Prospective Studies | Humans | Middle Aged | Male | Young Adult | Dihydropyrimidine Dehydrogenase Deficiency - complications | Neoplasms - blood | Dihydropyrimidine Dehydrogenase Deficiency - genetics | Fluorouracil - adverse effects | Drug-Related Side Effects and Adverse Reactions - genetics | Aged, 80 and over | Pharmacogenomic Variants | Adult | Female | Fluorouracil - metabolism | Uracil - blood | Thymidylate Synthase - metabolism | Genotype | Hospitalization | Biomarkers - blood | Pharmacogenomic Testing | Thymidylate Synthase - genetics | Neoplasms - drug therapy | Phenotype | Capecitabine - adverse effects | Alleles | Antimetabolites, Antineoplastic - adverse effects | Leukocytes, Mononuclear - enzymology | Aged | Drug-Related Side Effects and Adverse Reactions - mortality | Dihydrouracil Dehydrogenase (NADP) - metabolism | Dihydrouracil Dehydrogenase (NADP) - genetics | Uracil - analogs & derivatives | Index Medicus | Translational Therapeutics
Journal Article
International Journal of Cancer, ISSN 0020-7136, 01/2015, Volume 136, Issue 1, pp. 225 - 233
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2009, Volume 15, Issue 7, pp. 2344 - 2351
Journal Article
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, ISSN 0277-0008, 12/2019, Volume 39, Issue 12, pp. 1137 - 1145
Study Objective Enzalutamide is an oral agent for the treatment of metastatic castration‐resistant prostate cancer (mCRPC); N‐desmethyl enzalutamide is its... 
toxicity | prostate‐specific antigen | exposure | metabolites | response | enzalutamide
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 11/2002, Volume 99, Issue 24, pp. 15649 - 15654
The breast cancer resistance protein (BCRP/ABCG2) is a member of the ATP-binding cassette family of drug transporters and confers resistance to various... 
Diet | Phototoxicity | Bone marrow | Mice | Alfalfa | Lesions | Chlorophylls | Porphyrins | Bile | Food | OVEREXPRESSION | MITOXANTRONE | GENE | METABOLISM | MULTIDISCIPLINARY SCIENCES | TOPOTECAN | PORPHYRINS | CELL-LINES | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Diet - adverse effects | Porphyria, Hepatoerythropoietic - therapy | Chlorophyll - analogs & derivatives | Fetus - metabolism | Topotecan - toxicity | Medicago sativa - adverse effects | Porphyria, Hepatoerythropoietic - prevention & control | Chlorophyll - pharmacokinetics | Chromatography, High Pressure Liquid | Porphyrins - metabolism | Porphyrins - pharmacokinetics | ATP-Binding Cassette Transporters - physiology | Chlorophyll - administration & dosage | Photosensitizing Agents - administration & dosage | ATP-Binding Cassette Transporters - genetics | Neoplasm Proteins | Bone Marrow Transplantation | Female | Molecular Structure | Porphyria, Hepatoerythropoietic - genetics | Protoporphyrins - chemistry | Dermatitis, Phototoxic - etiology | Fibroblasts - metabolism | Chlorophyll - toxicity | Cell Line | Genetic Predisposition to Disease | Administration, Oral | Protoporphyrins - blood | Radiation Chimera | Mice, Inbred Strains | Dermatitis, Phototoxic - prevention & control | Mice, Knockout | Pregnancy | Drug Resistance - genetics | Animals | Photosensitizing Agents - toxicity | Topotecan - pharmacokinetics | Photosensitizing Agents - pharmacokinetics | Porphyria | Chlorophyll | Breast cancer | Research | Drug resistance | Photobiology | Antineoplastic agents | Antimitotic agents | Testolactone | Proteomics | Physiological aspects | Molecular biology | Observations | Photosensitivity disorders | Erythrohepatic porphyria | Adenosine triphosphate | Biological Sciences
Journal Article
Journal Article